Summary
Sixty-six post-menopausal women with metastatic breast cancer were randomised to receive tamoxifen or tamoxifen with aminoglutethimide. The women in the tamoxifen group were virtually free of toxicity, whilst 45% of patients in the aminoglutethimide group had toxicity and 13% discontinued the drug because of this. Responses were seen in 19% of patients receiving tamoxifen alone and 23% of those receiving both drugs. There is no indication that the increased toxicity seen with the addition of aminoglutethimide to tamoxifen in this situation is justified by an increased response rate.
References
Corkery J, Leonard RCF, Henderson IC, Gelman RS, Hourihan J, Ascoli JM, Salhanick HA (1982) Tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res (Suppl) 42:3409S-3414S
Harris AL, Powles TJ, Smith IE (1982) Aminoglutethimide in the treatment of advanced post-menopausal breast cancer. Cancer Res [Suppl] 42:3405S-3408S
Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89–94
Ingle JN, Green SJ, Ahmann DL, Edmonson JH, Nichols WC, Frytak S, Rubin J (1982) Progress report on two clinical trials in women with advanced breast cancer. Trial 1: tamoxifen versus tamoxifen plus aminoglutethimide; Trial II: aminoglutethimide in patients with prior tamoxifen exposure. Cancer Res [Suppl] 42:3461S-3464S
Mouridsen H, Palshoff T, Patterson J, Battersby L (1978) Tamoxifen in advanced breast cancer. Cancer Treat Rev 5:131–141
Ragaz J, Ibrahim E, Leaky M, Willam A (1981) A combination of hormones for metastatic breast cancer. Proc Am Assoc Cancer Res 22:145
Smith IE, Harris AL, Morgan M, Gazet J-C, McKinna JA (1982) Tamoxifen versus aminogluethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res [Suppl] 42:3430S-3433S
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Milsted, R., Habeshaw, T., Kaye, S. et al. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. Cancer Chemother. Pharmacol. 14, 272–273 (1985). https://doi.org/10.1007/BF00258132
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00258132